Home » Psychology news » AstraZeneca And Targacept Initiate Phase 2b Clinical Trial Of TC-5214 As A Switch Monotherapy Treatment For Major Depressive Disorder
AstraZeneca And Targacept Initiate Phase 2b Clinical Trial Of TC-5214 As A Switch Monotherapy Treatment For Major Depressive Disorder
February 9, 2011 by NewsBot
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD...
